Eton Pharma shareholders elect Jenn Adams, Charles Casamento to board, ratify auditor KMJ Corbin

Eton Pharmaceuticals, Inc.

Jenn Adams elected as director with 11,008,471 votes for, 393,816 against, 3,567 abstain.
Charles J. Casamento elected as director with 10,808,753 for, 594,949 against, 2,152 abstain.
Ratification of KMJ Corbin & Company LLP as independent auditor: 18,092,275 for, 63,090 against, 37,600 abstain.
Broker non-votes on director election: 6,787,111 per nominee; auditor ratification had 0 broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eton Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of KMJ Corbin & Company LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2023 at the 2023-06-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

Proposal 2: Ratification of the Appointment of KMJ Corbin & Company LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2023 For Against Abstain Broker Non-Votes 18,092,275 63,090 37,600 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eton Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

Proposal 1: Election of Directors Nominee For Against Abstain Broker Non-Votes Jenn Adams 11,008,471 393,816 3,567 6,787,111 Charles J. Casamento 10,808,753 594,949 2,152 6,787,111

View on SEC.gov

Browse all shareholder votes →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-021064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.